From her first days in the patent profession, Claire has been involved with many of the major innovations in the life sciences’ field. These have spanned immunology-related therapeutics, RNA therapeutics, synthetic biology and genetic diagnostics, including applications of bioinformatics. This continues as a partner of both the specialist HGF CRISPR and microbiome IP teams.
Claire has extensive experience of opposition and appeal proceedings at the European Patent Office, including both defending and opposing high profile patents which have attracted much interest beyond patent professionals. This has included patents from the early days of recombinant antibodies through to controversial patents arising from gene discovery and more recently, much publicised patents for gene-editing technologies.
Claire also has much experience of handling patent portfolios demanding inter-disciplinary input including in the fields of bioinformatics and medical and diagnostic devices. This has included much in the application of high-throughput nucleic acid sequencing technologies such as non-invasive foetal testing and cancer diagnostics.
As one of the most experienced patent partners’ of the life science team, Claire has the reputation of being able to apply creative thinking to turn around the most difficult IP problems. She has been responsible for building the IP portfolios of a number of companies and continues to enjoy the challenge of advising on freedom-to-operate and IP strategy.
MA(Oxon) Biochemistry with supplemental chemical pharmacology
PhD St George's Hospital Medical School
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.